A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

A new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

So is Ozempic safe? Novo Nordisk, the pharmaceutical company that makes Ozempic and Wegovy, stands behind the safety and efficacy of all its GLP-1 medicines when they’re used as indicated and ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

Danish firm Novo Nordisk, known for its bestsellers Ozempic and Wegovy, treatments for diabetes and weight loss, fell more than 20% on the stock market on Friday, after disappointing results of a ...

Novo Nordisk (NYSE:NVO) has secured approval from the European Medicines Agency (EMA) for a kidney disease-related label expansion for its blockbuster drug Ozempic (semaglutide) in Europe, on December ...

Ozempic maker Novo Nordisk saw its value fall by as much as £82billion yesterday after a weight loss drug trial fell short of expectations. It was one of the Danish pharma giant's worst days on ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...